Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.06 USD
Change Today +0.04 / 1.98%
Volume 8.8K
LPTN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

lpath inc-class a (LPTN) Key Developments

Lpath Inc. - Shareholder/Analyst Call

To update investors on the progress of Lpath's programs

Lpath Inc. Submits Investigational New Drug Application for Lpathomab for Neuropathic Pain

Lpath Inc. announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct a Phase 1 study of Lpathomab™ for the treatment of neuropathic pain. The primary objective of the study is to evaluate the safety and tolerability of Lpathomab in subjects that are experiencing neuropathic pain. Lpath plans to begin enrolling patients once the FDA's IND review period is complete and the study has been approved by the trial sites' investigational review boards. Lpathomab is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy.

Lpath Inc. - Special Call

To update on the progress of the Nexus trial as well as other programs

Lpath Announces Executive Changes

Lpath Inc. announced that Scott Pancoast has resigned as president, chief executive officer and a member of the board of directors, effective from November 3, 2014. The board of directors has appointed biotechnology consultant Michael Lack as the company's interim chief executive officer while the board conducts a search for a new CEO. Mr. Pancoast served as the president and CEO of Lpath since March 2005 and as a director of Lpath since 1998. Mr. Lack currently serves as a member of the board of directors of Immunomic Therapeutics Inc.

Lpath Mulls Acquisitions

Lpath Inc. (NasdaqCM:LPTN) is seeking acquisitions. Lpath Inc. has completed a follow-on equity offering in the amount of $12.53 million. Lpath said that it plans to raise funds via direct offering and plans to use part of proceeds for acquisitions too. Lpath said, "Lpath may also use a portion of the net proceeds to invest in or acquire businesses or technologies that it believes are complementary to its own, although it has no current plans, commitments or agreements with respect to any acquisitions as of the date hereof."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPTN:US $2.06 USD +0.04

LPTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LPTN.
View Industry Companies
 

Industry Analysis

LPTN

Industry Average

Valuation LPTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.0x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LPATH INC-CLASS A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.